注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Galecto Inc是一家临床阶段的生物技术公司。该公司专注于开发旨在针对位于纤维化核心的生物过程并影响广泛的纤维化和相关疾病(包括癌症)的疗法。该公司最初的重点是开发galectin-3和赖氨酰氧化酶样2(LOXL2)的小分子抑制剂。该公司正在开发GB0139,用于治疗严重的肺纤维化疾病,例如特发性肺纤维化(IPF),这是一种危及生命的进行性肺纤维化疾病。该公司的候选产品组合还包括GB1211,一种选择性口服半乳糖凝集素三抑制剂,正在开发用于治疗与非酒精性脂肪性肝炎(NASH)相关的纤维化以及GB2064,一种用于治疗骨髓纤维化的LOXL2选择性口服抑制剂,一种骨髓疾病,其中纤维化降低了形成血细胞的能力。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Hans T. Schambye | 57 | 2020 | Co-Founder, President, CEO & Director |
Carl S. Goldfischer | 64 | 2020 | Independent Chairman of the Board |
Chau Quang Khuong | 48 | 2015 | Independent Director |
Jayson Donald Alexander Dallas | 56 | 2020 | Independent Director |
Anne Prener | 66 | 2021 | Independent Director |
Mark Thursz | - | - | Member of Clinical Advisory Board – Liver Cirrhosis |
Stephen A. Harrison | - | - | Member of Clinical Advisory Board – Liver Cirrhosis |
Aaron Gerds | - | - | Member of the Clinical Advisory Board - Myelofibrosis |
Claire Harrison | - | - | Member of the Clinical Advisory Board - Myelofibrosis |
William L. Redmond | - | - | Member of Clinical Advisory Board – Oncology |
Raajit Rampal | - | - | Member of the Clinical Advisory Board - Myelofibrosis |
Adam Mead | - | - | Member of the Clinical Advisory Board - Myelofibrosis |
Amit D. Munshi | 56 | 2020 | Independent Director |
Jonathan Fallowfield | - | - | Member of Clinical Advisory Board – Liver cirrhosis |
Roy Steven Herbst | 61 | - | Member of Clinical Advisory Board – Oncology |
Søren Møller | 57 | 2020 | Independent Director |
David Shapiro | 70 | 2020 | Independent Director |
John Mascarenhas | - | - | Member of the Clinical Advisory Board - Myelofibrosis |
Alexander Maximiliaan Marie Eggermont | - | - | Member of Clinical Advisory Board – Oncology |
Michael Charlton | - | - | Member of Clinical Advisory Board – Liver cirrhosis |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核